Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281296 | 1.00 | HPGD (0.48) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL29792964 | 1.00 | HPGD (0.48) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL29424792 | 1.00 | HPGD (0.48) | HPGDKMT2AERCC5FEN1TSHR | |
| Water SCHEMBL8139522 | 0.98 | HPGD (0.47) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL6835363 | 0.84 | HPGD (0.42) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL6835963 | 0.84 | HPGD (0.42) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL10455866 | 0.81 | HPGD (0.46) | HPGDKMT2AERCC5FEN1MYC | |
| SCHEMBL19278858 | 0.81 | HPGD (0.46) | HPGDKMT2AERCC5FEN1MYC | |
| SCHEMBL27861393 | 0.80 | HPGD (0.46) | HPGDKMT2AERCC5FEN1TSHR | |
| SCHEMBL8193953 | 0.80 | ERCC5 (0.45) | HPGDKMT2AERCC5FEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | KURA ONCOLOGY INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | AARTI PHARMALABS LIMITED (IN) | 2022-12-22 | — | — | US | claimed |
| CN-108884081-B | Process for separating enantiomers of piperazine derivatives | 阿森纽荣股份公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4051681-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | Aarti Industries Limited (IN) | 2022-09-07 | — | — | EP | claimed |
| EP-1311265-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT INC (US) | 2004-12-29 | — | — | EP | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| US-6743812-B1 | 2,3-DIACYLTARTARIC ACID SALTS OF E-METANICOTINE; NERVOUS SYSTEM DISORDERS; AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES | TARGACEPT, INC. | 2004-06-01 | — | — | US | claimed |
| EP-1317267-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | Targacept, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| EP-1311265-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | Targacept, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | claimed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| JP-3223236-A | — | — | None | — | — | JP | disclosed |
| CN-122055355-A | Compounds for the treatment of diabetes and related disorders | 奥克兰联合服务有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-3944589-A | α-Cycloalkenylphenyl-fatty acid nitriles | CIBA-GEIGY CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
| US-3935259-A | 2-HYDROXY-3-(UREIDOPHENOXY)PROPYL, CARDIAC BETA RECEPTOR INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1976-01-27 | — | — | US | disclosed |
| US-3933802-A | New sulphamoylbenzoic acid amides | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125390-A1 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | FDPS, PCTP, MTTP | HPGD 3517/4885KMT2A 4366/4885ERCC5 4289/4885 |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | HPGD 2818/4885KMT2A 3828/4885ERCC5 3326/4885 |
| US-20220402924-A1 | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES THEREOF | MCCC2, JAK1, JAK3 | HPGD 2733/4885KMT2A 851/4885ERCC5 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.